Baxdrostat, a once-daily pharmaceutical pill designed to block the hormone aldosterone, has demonstrated the unexpected ability to reverse a common underlying cause of high blood pressure for up to two years after patients stopped taking the medication, according to findings published in the New England Journal of Medicine.
More than a billion people globally live with high blood pressure, medically defined as hypertension. In approximately 5% to 10% of these cases, the condition stems from small, benign nodules or tumors on the adrenal glands.
These growths cause the glands to overproduce aldosterone, a hormone that signals the kidneys to retain salt and water, thereby driving up blood pressure. Traditionally, this specific form of the condition—known as primary aldosteronism—requires surgical removal of the affected adrenal gland, though surgery does not always resolve the hypertension entirely.
Baxdrostat Inhibits Aldosterone Synthase to Normalize Blood Pressure
- Targeting the Source: Baxdrostat is an aldosterone synthase inhibitor (ASI) that blocks the body from manufacturing the hormone responsible for salt retention in the kidneys.
- The Sustained Effect: In a small cohort of patients, taking the daily tablet for several months led to normalized blood pressure that persisted for up to two years after the medication was completely discontinued.
- Cellular Destruction: Researchers hypothesize that the drug causes a surge of reactive oxygen species that selectively destroy the overactive hormone-producing cells in the adrenal glands.
Clinical Trials Show Baxdrostat Lowers Blood Pressure Significantly
The potential curative properties of baxdrostat emerged from an analysis of a broader clinical trial. In the primary phase involving 796 patients across 214 clinics worldwide, the drug lowered blood pressure by 9 to 10 mmHg more than a placebo over a three-month period. Approximately 40% of patients taking the medication achieved a healthy blood pressure level, compared to fewer than 20% in the placebo group.
Following this initial phase, a smaller subset of 14 patients who experienced dramatic improvements continued taking the daily pills for six to 12 months before stopping. When clinicians evaluated these individuals up to two years later, their blood pressure remained much lower. These patients saw an average fall of 25 millimeters of mercury in their systolic blood pressure during the evaluation period, with nearly a quarter coming off all other hypertension treatments entirely.
The medication secured approval in the United States earlier in the year for patients whose blood pressure remains uncontrolled by existing multidrug regimens. In the United Kingdom, the National Institute for Health and Care Excellence (Nice) is currently evaluating baxdrostat, with potential NHS availability anticipated next year for eligible patients with treatment-resistant hypertension.
Evaluating the Proposed Cellular Mechanism
The longevity of the clinical response has shifted scientific focus toward the cellular environment of the adrenal glands. Professor Morris Brown, a hypertension specialist at Queen Mary University of London who led the study, pointed to experiments conducted in mice two decades ago, which demonstrated that deleting the gene responsible for aldosterone production led to the elimination of the cells that created it.
Suppressing aldosterone creates a local surge of highly active molecules known as reactive oxygen species, or oxygen radicals. These molecules appear to target and destroy the benign tumour cells overproducing the hormone, effectively inducing a medical remission that mimics the physical removal of the gland.
Harvard University professor of medicine Mason Freeman, who was involved in the research, noted that it remains premature to declare individual patients definitively cured. A larger clinical trial is currently underway to determine whether this sustained remission is statistically common across the broader population of hypertensive patients.
| Trial Parameter | Baxdrostat Group | Placebo Group |
|---|---|---|
| Patient Cohort Size | 796 participants | Standard comparator |
| Blood Pressure Drop (3 Months) | 9–10 mmHg greater reduction | Baseline reduction |
| Target Blood Pressure Reached | ~40% of patients | <20% of patients |
| Long-Term Follow-Up Duration | Up to 2 years post-cessation | N/A |
Baxdrostat Targets Patients with Treatment-Resistant Hypertension
Baxdrostat is currently intended for specific patient populations, particularly those with treatment-resistant hypertension where blood pressure remains dangerously elevated despite concurrent use of two or more standard medications.
Future Trajectory and Access
If larger trials confirm that baxdrostat's cellular effects last, doctors might change how they diagnose and treat primary aldosteronism. Rather than relying on invasive diagnostic imaging and major adrenal surgery, clinicians might utilize an aldosterone synthase inhibitor as an initial diagnostic and therapeutic intervention.
Regulatory decisions by health authorities such as Nice in the UK will dictate how rapidly this once-a-day pharmacological alternative moves from clinical investigation into routine clinical practice.
References
- New England Journal of Medicine: Clinical trial findings on baxdrostat and aldosterone suppression
Earlier coverage: Baxdrostat may permanently cure hypertension caused by tumours
